Should I Buy PMI? PMI 2026 Analysis

Should You Buy Picard Medical Inc (PMI) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.750

1 Day change

-2.78%

52 Week Range

13.680

Analysis Updated At

2026/01/30

PMI is not a good buy right now. With no Intellectia buy signals, neutral/indecisive technicals, a weak pre-market tape (-3.89%), and no near-term news catalysts, the risk/reward is not attractive for an impatient buyer. I would avoid initiating a new position at $1.78 today; if already holding, this is a hold (not an add).

Technical Analysis

Trend/Setup: Mixed-to-neutral. RSI(6) ~49 indicates no momentum edge. MACD histogram is above zero (bullish bias) but positively contracting, implying upside momentum is fading rather than accelerating. Moving averages are converging, consistent with consolidation and no clear trend. Key levels: Pivot 1.798 is the immediate decision zone. Support: 1.63 (S1), then 1.526 (S2). Resistance: 1.966 (R1), then 2.07 (R2). With price at 1.78 (below the pivot) and pre-market weakness, near-term odds favor chop/down-to-support unless buyers reclaim ~1.80 and push toward ~1.97. Pattern-based projection: Similar-candlestick model shows a bullish tilt (70% chance of gains), but the expected moves are modest near-term (+1.08% next day) and don’t override the lack of confirming momentum signals. Intellectia Proprietary Trading Signals - [AI Stock Picker](module://ai_stock_pick): no signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently.

Options Data

Positive Catalysts

Revenue grew +34.73% YoY in 2025/Q3; net loss and EPS improved YoY (loss narrowing); upcoming earnings on 2026-02-13 (pre-market) can act as an event catalyst if results/guide surprise to the upside; pattern-based model leans modestly bullish near term.

Neutral/Negative Catalysts

Gross margin is deeply negative and deteriorated YoY (operating quality concern); company remains meaningfully unprofitable (net income still -10.426M in 2025/Q3); no news flow in the last week (no fresh catalyst); pre-market down -3.89% suggests weak immediate demand; nearby supports at 1.63/1.526 could be tested if sellers persist.

Financial Performance

Latest quarter: 2025/Q3. Revenue increased to 1,187,000 (+34.73% YoY), but profitability remains very weak: net income -10,426,000 (improved +51.34% YoY but still a large loss) and EPS -0.14 (improved +40% YoY). The biggest red flag is gross margin turning/remaining deeply negative and falling sharply YoY (to -10.95), indicating poor unit economics/production or cost structure issues despite top-line growth.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so Wall Street pro/con positioning can’t be confirmed from this dataset. From fundamentals shown: Pros—strong YoY revenue growth and narrowing losses. Cons—severely negative/deteriorating gross margin and ongoing large losses, which typically suppress professional bullish conviction. Influential trading: Hedge funds neutral; insiders neutral; no recent Congress trading data available.

Analyst Rating

Wall Street analysts forecast PMI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PMI is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 1.800

Low

Averages

High